Isoprenoids, small GTPases and Alzheimer's disease
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The mevalonate-pathway is a crucial metabolic pathway for most eukaryotic cells. Cholesterol is a highly recognized product of this pathway but growing interest is being given to the synthesis and functions of isoprenoids. Isoprenoids are a complex class of biologically active lipids including for example, dolichol, ubiquinone, farnesylpyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). Early work had shown that the long-chain isoprenoid dolichol is decreased, but that dolichyl-phosphate and ubiquinone are elevated in brains of Alzheimer´s diseased (AD) patients. Until recently, levels of their biological active precursors FPP and GGPP were unknown. These short-chain isoprenoids are critical in the post translational modification of certain proteins which function as molecular switches in numerous, signaling pathways. The major protein families belong to the superfamily of small GTPases, consisting of roughly 150 members. Recent experimental evidence indicated that members of the small GTPases are involved in AD pathogenesis and stimulated interest in the role of FPP and GGPP in protein prenylation and cell function. A straightforward prediction derived from those studies was that FPP and GGPP levels would be elevated in AD brains as compared with normal neurological controls. For the first time, recent evidence shows significantly elevated levels of FPP and GGPP in human AD brain tissue. Cholesterol levels did not differ between AD and control samples. One obvious conclusion is that homeostasis of FPP and GGPP but not of cholesterol is specifically targeted in AD. Since prenylation of small GTPases by FPP or GGPP is indispensable for their proper function we are proposing that these two isoprenoids are up-regulated in AD resulting in an over abundance of certain prenylated proteins which contributes to neuronal dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“Pronounced loss of neurites and synapses represents one of themost relevant histopathological lesions in AD brain with respect to neuronal function [147–149].”
BackgroundTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Rab proteins as membrane organizers
Zerial, M., & McBride, H. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052055 · Cited by 3,381 · cited 1×
“[75–78]).”
Dietschy, J. M., & Turley, S. D. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400004-jlr200 · Cited by 1,095 · cited 1×
“Age-related processes in the brain have been extensively studied [98,99] and changes in various lipid have been examined with several studies on cholesterol homeostasis [100,101].”
BackgroundLow cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10
Kojro, E., Gimpl, G., Lammich, S., März, W., & Fahrenholz, F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081612998 · Cited by 804
Yankner, B. A., Lu, T., & Loerch, P. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.2.010506.092044 · Cited by 677
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620
Regulation of Sterol Synthesis in Eukaryotes
Espenshade, P. J., & Hughes, A. L. (2007) · Annual Review of Genetics · doi:10.1146/annurev.genet.41.110306.130315 · Cited by 593
Synaptic degeneration in Alzheimer's disease
Arendt, T. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0536-x · Cited by 517 · cited 1×
“Failures of synaptic plasticity are thought to represent early events in AD [150,151].”
BackgroundStructural Correlates of Cognition in Dementia: Quantification and Assessment of Synapse Change
DeKosky, S. T., Scheff, S. W., & Styren, S. D. (1996) · Neurodegeneration · doi:10.1006/neur.1996.0056 · Cited by 405
DeBose-Boyd, R. A. (2008) · Cell Research · doi:10.1038/cr.2008.61 · Cited by 391
Rho proteins, mental retardation and the cellular basis of cognition
Ramakers, G. J. A. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02118-4 · Cited by 374
Evolution of the Aging Brain Transcriptome and Synaptic Regulation
Loerch, P. M., Lu, T., Dakin, K. A., Vann, J. M., Isaacs, A., Geula, C., Wang, J., Pan, Y., Gabuzda, D. H., Li, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003329 · Cited by 334
Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß 42 by Inhibiting Rho
Zhou, Y., Su, Y., Li, B., Liu, F., Ryder, J. W., Wu, X., Gonzalez-DeWhitt, P. A., Gelfanova, V., Hale, J. E., May, P. C., et al. (2003) · Science · doi:10.1126/science.1090154 · Cited by 316
Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease
Distelmaier, F., Koopman, W. J. H., van den Heuvel, L. P., Rodenburg, R. J., Mayatepek, E., Willems, P. H. G. M., & Smeitink, J. A. M. (2008) · Brain · doi:10.1093/brain/awp058 · Cited by 310
Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease
Valenza, M., Rigamonti, D., Goffredo, D., Zuccato, C., Fenu, S., Jamot, L., Strand, A., Tarditi, A., Woodman, B., Racchi, M., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3355-05.2005 · Cited by 298
Mechanisms of Statin-mediated Inhibition of Small G-protein Function
Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A., & Landreth, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505268200 · Cited by 235 · cited 1×
“There is keen interest in the role of FPP and GGPP in posttranslational modification of proteins and cell function in Alzheimer's disease (AD) [3,12,13].”
BackgroundNeurotoxic Activation of Microglia Is Promoted by a Nox1-Dependent NADPH Oxidase
Chéret, C., Gervais, A., Lelli, A., Colin, C., Amar, L., Ravassard, P., Mallet, J., Cumano, A., Krause, K.-H., & Mallat, M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3568-08.2008 · Cited by 225
Statins Reduce Amyloid-β Production through Inhibition of Protein Isoprenylation
Ostrowski, S. M., Wilkinson, B. L., Golde, T. E., & Landreth, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702640200 · Cited by 180 · cited 2×
“Recent experimental evidence indicates that isoprenylated small GTPases are involved in Alzheimer disease pathogenesis [3,91–94].”
BackgroundIdebenone treatment fails to slow cognitive decline in Alzheimer’s disease
Thal, L. J., Grundman, M., Berg, J., Ernstrom, K., Margolin, R., Pfeiffer, E., Weiner, M. F., Zamrini, E., & Thomas, R. G. (2003) · Neurology · doi:10.1212/01.wnl.0000096376.03678.c1 · Cited by 156
Modulation of Statin-Activated Shedding of Alzheimer APP Ectodomain by ROCK
Pedrini, S., Carter, T. L., Prendergast, G., Petanceska, S., Ehrlich, M. E., & Gandy, S. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020018 · Cited by 154 · cited 1×
“Activation of effectors downstream of prenylated small GTPases, such as the protein kinases ROCK (Rho associated coiled-coil forming protein kinase) have been implicated in APP metabolism [134,135].”
BackgroundYang, X., Yang, Y., Li, G., Wang, J., & Yang, E. S. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-9033-7 · Cited by 111 · cited 1×
“Experimental studies in animal AD models suggest that ubiquinone may protect against neuronal damage [116].”
BackgroundPresenilins interact with Rab11, a small GTPase involved in the regulation of vesicular transport
Dumanchin, C. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.7.1263 · Cited by 99
Cited by
Linking lipids to Alzheimer's disease: cholesterol and beyond
Di Paolo, G., & Kim, T.-W. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3012 · Cited by 972
“The 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase) pathway, also called the mevalonate pathway, not only leads to the synthesis of cholesterol but also provides eukaryotic cells with essential lipids, such as isoprenoids (recently reviewed in Ref”
BackgroundProtein prenylation: unique fats make their mark on biology
Wang, M., & Casey, P. J. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.11 · Cited by 547
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
Aging and Alzheimer's disease: comparison and associations from molecular to system level
Xia, X., Jiang, Q., McDermott, J., & Han, J. J. (2018) · Aging Cell · doi:10.1111/acel.12802 · Cited by 301
Schultz, B. G., Patten, D. K., & Berlau, D. J. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0110-3 · Cited by 229
“Isoprenoids, particularly farsenylpyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), have recently been shown to be elevated in human AD brain tissue [71] and statins have been shown to reduce the amount of mevalonate, a precursor to FPP and GGPP.”
Background
Metadata
- Authors
- Hooff, G. P., Wood, W. G., Müller, W. E., & Eckert, G. P.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 1801
- Issue
- 8
- Pages
- 896-905
- ISSN
- 1388-1981 (ISSN-L)
- OpenAlex
- W2013382634
- Cited by
- 102
- References
- 24
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.